Loading…
Monte Rosa Therapeutics, Inc. is projected to rise to $36.32 by 2027, a +58% move from its current price of $23.04. GLUE is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $22.32 | $23.05 | $23.81 | +0.06% |
| Jul 14 | $22.04 | $23.07 | $24.15 | +0.12% |
| Jul 15 | $21.82 | $23.08 | $24.41 | +0.18% |
| Jul 16 | $21.65 | $23.10 | $24.64 | +0.24% |
| Jul 17 | $21.50 | $23.11 | $24.85 | +0.30% |
| Jul 18 | $21.36 | $23.12 | $25.03 | +0.36% |
| Jul 19 | $21.24 | $23.14 | $25.21 | +0.43% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $21.24 | $23.14 | $25.21 | +0.43% |
| Week 2 | $20.59 | $23.24 | $26.23 | +0.85% |
| Week 3 | $20.12 | $23.34 | $27.07 | +1.28% |
| Week 4 | $19.74 | $23.43 | $27.81 | +1.71% |
| Week 5 | $19.43 | $23.53 | $28.50 | +2.15% |
| Week 6 | $19.16 | $23.63 | $29.15 | +2.58% |
| Week 7 | $18.92 | $23.74 | $29.77 | +3.02% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company that develops novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. Its approach includes orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns.
The company also develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast, and its pipeline spans immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. It operates QuEEN, a discovery engine to enable its target-centric MGD discovery and development approach and the rational design of MGD product candidates. It has strategic collaborations with Roche and Novartis and was incorporated in 2019, with headquarters in Boston, Massachusetts.
GLUE is the stock symbol for Monte Rosa Therapeutics, Inc. It has a current price of $23.90 and a market capitalization of $2.02B, with a market rank of 1946.
The price outlook inferred from the available forecast shows a path of appreciation over time, with the forecasted average price rising from $23.90 in 2026 to $38.80 in 2027 and to $59.28 in 2030, continuing higher in later years.
Long-horizon forecasts project substantial further gains, with the average price reaching $233.16 by 2040 and $478.37 by 2050, accompanied by rising ROI figures in the later years (e.g., ROI 62.4 in 2027, 148 in 2030, and 1,901.6 by 2050).
A major floor 42.9% below — a decisive break under it would weaken the trend.
The nearest floor, 28.9% below — buyers have tended to step in here.
The nearest ceiling, 6.4% above — a clean break opens room to run.
A major ceiling 27.9% above — clearing it would confirm fresh momentum.
Key GLUE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GLUE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $23.85 | Sell | $23.73 | Sell |
| MA 10 | $23.79 | Sell | $23.24 | Sell |
| MA 20 | $21.39 | Buy | $22.00 | Buy |
| MA 50 | $19.73 | Buy | $20.29 | Buy |
| MA 100 | $18.70 | Buy | $19.05 | Buy |
| MA 200 | $17.05 | Buy | $16.66 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 59.59 | Neutral |
| Stoch RSI (14) | 22.07 | Neutral |
| CCI (20) | 45.37 | Neutral |
| Williams %R (14) | -25.30 | Info |
| MACD (12,26,9) | 0.18 | Buy |
| ROC (12) | 11.25 | Buy |
| Bollinger %B (20,2) | 0.66 | Neutral |
| Stochastic %K (14) | 74.70 | Neutral |
| TRIX (15) | 0.97 | Buy |
| Awesome (5,34) | 3.80 | Buy |
| Ultimate (7,14,28) | 50.70 | Neutral |
| Momentum (10) | 1.38 | Buy |
| Aroon Osc (25) | 88.00 | Buy |
| Hull MA (9) | 24.03 | Sell |
| ADX (14) | 30.34 | Buy |
| ATR (14) | 0.66 | Info |
The near-term technical picture is bullish, with sentiment labeled BULLISH, and RSI14 at 80. The 50-day simple moving average stands at $19.09 while the 200-day simple moving average sits at $16.34, suggesting the price is hovering above key moving averages.
Support is reported at $16.37 and resistance at $23.90, framing a constructive backdrop as the price trades within a tighter range around the current level.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $14.40 | $23.04 | $33.95 | 0% | Neutral | |
| $28.41 | $36.32 | $49.41 | +58% | Bullish | |
| $30.88 | $40.83 | $57.97 | +77% | Bullish | |
| $35.44 | $48.19 | $70.73 | +109% | Bullish | |
| $39.21 | $54.67 | $82.50 | +137% | Bullish | |
| $42.02 | $59.94 | $92.67 | +160% | Bullish | |
| $47.82 | $69.68 | $110.10 | +202% | Bullish | |
| $60.24 | $89.56 | $144.30 | +289% | Bullish | |
| $74.11 | $112.32 | $184.26 | +388% | Bullish | |
| $76.96 | $118.80 | $198.16 | +416% | Bullish | |
| $123.21 | $206.98 | $370.05 | +798% | Bullish | |
| $213.48 | $416.30 | $822.78 | +17.1x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $14.40 | $23.04 | $27.84 | +0.00% |
| August 2026 | $19.52 | $23.16 | $28.31 | +0.53% |
| September 2026 | $20.35 | $24.35 | $30.15 | +5.14% |
| October 2026 | $21.53 | $25.94 | $32.47 | +6.54% |
| November 2026 | $21.66 | $26.26 | $33.17 | +1.23% |
| December 2026 | $21.86 | $26.65 | $33.95 | +1.49% |
Click any year to see its month-by-month GLUE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, GLUE could reach as high as $33.95, with a base case around $23.04 and support toward $14.40 — roughly 0% from $23.04. Price action looks broadly range-bound.
Expect GLUE to range from $28.41 to $49.41 through 2027. The $36.32 average target implies a +58% move from current prices. That is up +58% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The GLUE price prediction for 2028 points to an average of $40.83 (low $30.88, high $57.97) — a potential gain of +77% on today's $23.04. Momentum favours further upside here.
In 2029, GLUE is projected to trade between $35.44 and $70.73, averaging $48.19 — a potential gain of +109% from today's $23.04. That is up +18% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Monte Rosa Therapeutics, Inc.'s 2030 outlook centres on $54.67, within a $39.21 to $82.50 range. That is up +13% on the projected 2029 average. That marks a +137% change versus current levels. Momentum favours further upside here.
By 2031, GLUE could reach as high as $92.67, with a base case around $59.94 and support toward $42.02 — roughly +160% from $23.04. Buyers look set to stay in control over this stretch.
Expect GLUE to range from $47.82 to $110.10 through 2032. The $69.68 average target implies a +202% move from current prices. That is up +16% on the projected 2031 average. Momentum favours further upside here.
The GLUE price prediction for 2033 points to an average of $89.56 (low $60.24, high $144.30) — a potential gain of +289% on today's $23.04. Buyers look set to stay in control over this stretch.
In 2034, GLUE is projected to trade between $74.11 and $184.26, averaging $112.32 — a potential gain of +388% from today's $23.04. That is up +25% on the projected 2033 average. Momentum favours further upside here.
Monte Rosa Therapeutics, Inc.'s 2035 outlook centres on $118.80, within a $76.96 to $198.16 range. That is up +6% on the projected 2034 average. That marks a +416% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, GLUE could reach as high as $370.05, with a base case around $206.98 and support toward $123.21 — roughly +798% from $23.04. Momentum favours further upside here.
Expect GLUE to range from $213.48 to $822.78 through 2050. The $416.30 average target implies a +17.1x move from current prices. That is up +101% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in GLUE today (≈ 43.402778 GLUE) could be worth
$18,068.52
+$17,068.52 (+1707%) by 2050 · US Dollar
Based on the average projected GLUE price of $416.3 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GLUEwould be worth at today's price.
$1,000 invested in GLUE on Jul 10, 2025 (≈ 190.11406 GLUE) would be worth
$4,380.23
+$3,380.23 (+338.0%) today · 4.38× · US Dollar
Based on a GLUE entry price of $5.26 vs. today's $23.04.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $24.21 | $951.67 | -4.8% |
| 1 month ago | $16.52 | $1,394.67 | +39.5% |
| 3 months ago | $17.48 | $1,318.08 | +31.8% |
| 6 months ago | $23.72 | $971.33 | -2.9% |
| 1 year ago | $5.26 | $4,380.23 | +338.0% |
| All time (5.0y) ago | $18.59 | $1,239.38 | +23.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GLUE forecast.
Our base-case forecast reaches $46.00 around 2029.
Implied market cap at $46.00: $3.89B
The multi-year forecast portrays a sustained bullish trajectory. The average price is projected to rise from $23.90 in 2026 to $59.28 in 2030, then to $233.16 in 2040 and $478.37 in 2050, reflecting a long-run growth path. Notable milestones include 2027 with an avg of $38.80 and ROI of 62.4, 2028 with an avg of $42.73 and ROI of 78.8, 2029 with an avg of $52.18 and ROI of 118.3, and 2033 with an avg of $100.45 and ROI of 320.3.
Forecasted ROIs accelerate meaningfully in the out years, reaching 148 in 2030, 164.5 in 2031, 223.3 in 2032, 320.3 in 2033, 416 in 2034, 455.9 in 2035, 875.6 in 2040, and 1,901.6 in 2050. These figures imply a strong long-term appreciation path, albeit with the inherent uncertainty and risk attached to long-horizon projections. Investment outcomes are not guaranteed and depend on future market and company-specific developments.
Tap a question to reveal the answer.
According to the forecast, the 2030 average price is $59.28 with a min of $41.95 and a max of $90.77; ROIPct = 148; sentiment = BULLISH.
The forecast shows bullish sentiment in most years from 2027 onward and rising average prices, with notable long-term appreciation (e.g., 2027 avg $38.80, 2030 avg $59.28, 2040 avg $233.16, 2050 avg $478.37). However, the 2026 year is neutral with an ROI of 0, and these are estimates, not guarantees.
Yes. The forecast lists 2033 with an avg of $100.45, a min of $66.34, a max of $164.63, and ROI of 320.3; sentiment for that year is BULLISH.
Current price is $23.90 and market capitalization is $2.02B.
The near-term setup is bullish with RSI14 at 80, SMA50 at $19.09, and SMA200 at $16.34. Support is at $16.37 and resistance at $23.90. The 30-day range runs from $19.06 to $29.96, and annualized volatility is 70%.
Monte Rosa Therapeutics, Inc. Community Discussion
0Share your Monte Rosa Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.